Facilitated By

San Antonio Medical Foundation

News

  • San Antonio manufacturing sector makes a $40.5 billion economic impact

    Butler and Stefl said it is difficult to determine San Antonio's largest economic sector because they study the sectors in different years. For 2015, the health care and biosciences sector's economic impact was reported at $37 billion, but it now might be about the same as manufacturing as the…

  • Galectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial Failure

    Galectin Therapeutics Inc (NASDAQ:GALT) is crash-landing 35% to the market floor once investors caught word of the biotech firm's Phase 2b ... medical director of Pinnacle Clinical Research in San Antonio, Texas, and visiting professor of medicine at the University of Oxford, United Kingdom.

  • Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with ...

    ... in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium ... 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and…

  • Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with ...

    05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and ... a first-in-class glutaminase inhibitor, will be presented at the 2017 San Antonio Breast Cancer Symposium, December 5-9, 2017 in San Antonio, Texas.

  • Galectin drops 40% on negative NASH result

    It's rarely ever a positive sign when a biotech has to resort to slicing and dicing data in order to find a positive result. ... for the presence of esophageal varices," said Stephen Harrison, one of lead investigators of the NASH-CX trial and medical director of Pinnacle Clinical Research in…